Advanced Pancreatic Neuroendocrine Tumors (pNETs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Advanced Pancreatic Neuroendocrine Tumors (pNETs) Market Outlook

Thelansis’s “Advanced Pancreatic Neuroendocrine Tumors (pNETs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced pancreatic neuroendocrine tumors treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced Pancreatic Neuroendocrine Tumors (pNETs) Overview

Advanced pancreatic neuroendocrine tumors (NETs) are a rare and complex form of cancer that develops in the neuroendocrine cells of the pancreas. These cells have dual characteristics, functioning both as hormone-producing endocrine cells and as nerve-like cells. Unlike the more common exocrine pancreatic cancers, NETs are less prevalent but can vary significantly in their behavior, ranging from slow-growing to highly aggressive forms. In advanced stages, these tumors often spread beyond the pancreas to other parts of the body, such as the liver, bones, or lymph nodes. Symptoms can be diverse and depend on whether the tumor is functioning (producing hormones) or non-functioning. Functioning tumors may lead to hormone-related symptoms like diarrhea, flushing, or hypoglycemia, while non-functioning tumors often present with non-specific symptoms such as abdominal pain, weight loss, or jaundice.

Advanced pancreatic NETs management is challenging and typically involves a multidisciplinary approach. Treatment options may include surgery, if feasible, to remove the primary tumor or metastatic lesions. For inoperable cases, therapies such as somatostatin analogs, targeted therapies like everolimus or sunitinib, peptide receptor radionuclide therapy (PRRT), and chemotherapy are commonly used. Advances in molecular and genetic profiling have also paved the way for more personalized treatment strategies, aiming to improve outcomes and quality of life for patients.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2024-2034

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: